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Summary
Invasive aspergillosis (IA) is a disease of the
immunocompromised with a predilection for the lungs,
although dissemination to all organs is possible. Its
diagnosis remains a challenge due to the absence of
specific clinical manifestations and laboratory findings.
In most cases, diagnosis is eventually made via invasive
methods. It carries with it a high mortality due to late
diagnosis and delayed treatment. Here, we report
a fascinating case of a young, otherwise healthy,
immunocompetent patient that presented to us with
superior vena cava syndrome and a mediastinal mass.
It was anticipated that a malignancy would be found
on further workup but, in fact, what was eventually
discovered was a case of IA. Our report accentuates
the significance of including IA as a differential while
diagnosing a mediastinal mass in an immunocompetent
host as patient outcome is determined by timely
diagnosis and treatment.

Background

Aspergillosis comprises a spectrum of diseases
related to host factors.1–3 Invasive aspergillosis
(IA) is a disease of concern due to high mortality
in transplant recipients and patients with haematological malignancies. Although rare, its occurrence
has been reported in immunocompetent hosts, with
multisystem involvement.4–6 Here, we present a

Figure 2 Chest X-ray showing widened mediastinum,
elevated right hemidiaphragm and blunting of the right
costophrenic angle.
case of a young immunocompetent man presenting
with signs of superior vena cava (SVC) obstruction
and a mediastinal mass. Suspicion of a malignancy
was high but on biopsy was found to have IA of the
mediastinum.

Case presentation

A 28-year-old man was referred to our pulmonary
outpatient clinic (Aga Khan University Hospital,
Karachi) for the workup of a mediastinal mass. He
had a 12-month history of right-sided chest pain,
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Figure 1 Right anterior neck and chest wall showing
prominent neck and chest wall veins and mediastinotomy
scar.

Figure 3 CT of the chest. (A) Lung window showing
right anterior mediastinal mass with right-sided effusion.
(B) Mediastinal window showing mediastinal mass
occluding right main bronchus. (C) Coronal section
showing invasion of the mediastinal structures.

Rahim Y, et al. BMJ Case Rep 2018. doi:10.1136/bcr-2018-225614

1

BMJ Case Reports: first published as 10.1136/bcr-2018-225614 on 12 September 2018. Downloaded from http://casereports.bmj.com/ on 27 January 2020 by guest. Protected by copyright.

Rare disease

Figure 4 Periodic acid-Schiff stain highlighting mostly fungal spores,
rare hyphae seen.
with radiation to the back. He also complained of shortness of
breath, reduced appetite, weight loss, difficulty swallowing and
swelling of his face and neck for the past 5 months. He denied
fever, night sweats, cough or past tuberculosis (TB) contact. He
had a history of smoking in the distant past, that is, 2 years of
smoking around 10 years ago. He denied alcohol and illicit drug
use. He sought medical attention 6 months after his symptoms
began in his hometown. He was started on treatment for asthma,
that is, inhaled corticosteroids and inhaled long-acting beta-agonist and a 3-week tapering dose of oral prednisolone (starting
at 10 mg twice a day) with no improvement whatsoever. A chest
X-ray (CXR) was ordered and a suspicious finding on that led to
a CT of the thorax, which showed a mediastinal mass. Despite
two negative sputum samples for acid-fast bacilli (AFB), he was

Figure 6 Gomori methenamine-silver stain, highlighting fungal
bodies.
started on empiric antituberculous therapy. This was discontinued after 3 weeks as there was no clinical improvement.
He was then referred to us for further workup and management with a strong suspicion of malignancy (likely lymphoma).
On initial assessment, vital signs were within normal values.
There was evidence of congested neck, prominent chest wall
veins and facial plethora (figure 1).
Chest examination revealed absent breath sounds on the
lower one-third of the right posterior chest and an otherwise
unremarkable cardiovascular and systemic examination.

Investigations

Laboratory tests were normal. CXR was concerning for a
widened mediastinum and right-sided effusion (figure 2).
Diagnostic thoracentesis revealed a lymphocyte dominant
exudate, a white cell count of 6.673×109/L (lymphocytes 95%),
protein of 4.8 g/dL, glucose of 88 mg/dL and Lactate dehydrogenase (LDH) of 323 U/L. Pleural fluid cytology revealed no
malignant cells. Serological testing for HIV was negative. Serum
immunoglobulin (IgG, IgA, IgM) levels were within normal
range.
CT thorax showed an 11×9×8 cm mass centred in the anterior and middle mediastinum, more on the right side. It showed
invasion of the right atrium, right pulmonary artery with partial

Figure 5 Periodic acid-Schiff stain highlighting mostly fungal spores,
rare hyphae seen.
2

Figure 7 Aspergillus colonies.
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invasion of the left atrium and left inferior pulmonary vein.
Partial obliteration of the right main stem bronchus was noted
along with narrowing of the SVC and prominent collaterals
(figure 3A–C).

Outcome and follow-up

He underwent anterior mediastinotomy, with mediastinal
mass biopsy, revealing non-necrotising granulomas, with
multinucleated giant cells and histiocytes. Scant fragments
of fibrocollagenous tissue noted. Periodic acid-Schiff and
Gomori methenamine-silver stains highlighted occasional
septate fungal hyphae (figures 4, 5 and 6). Mycology cultures
grew the Aspergillus flavus complex (figure 7). Mediastinal tissue
AFB smear and culture were negative.
Therapy with oral voriconazole 400 mg twice a day for 1 day
followed by 200 mg twice a day was started after histological
confirmation, and the patient was asked to follow up in 4 and
then 8 weeks, while continuing therapy. Patient showed marked
improvements in symptoms with progressive weight gain and
increased oral intake. Repeat CT scan is planned at 6 months to
look for mass resolution.

Discussion

To the best of our knowledge, this is the second case of SVC
obstruction secondary to IA of the mediastinum in an immunocompetent host published in the literature. Association with
other infectious diseases namely syphilis, TB, histoplasmosis and
actinomycosis have been described.
Aspergillus is a spore-forming saprophytic fungus, ubiquitous
to the environment. With approximately 200 species, Aspergillus
fumigatus is the most commonly isolated pathogen.
Aspergillus species cause a broad spectrum of disease, ranging
from hypersensitivity reactions to direct angioinvasion. The lung
is the most common site of infection with disease ranging from
allergic bronchopulmonary aspergillosis, chronic necrotising
pneumonia, aspergilloma and IA.6
IA is primarily a disease of immunocompromised patients, with
prolonged neutropenia constituting a predominant risk factor,7
followed by haematopoietic stem cell transplants or solid organ
transplants (especially lung transplantation) and advanced
AIDS.8 9 In the above population of patients, host factors govern
the risk and clinicopathological features of invasive disease.1 2
Rarely invasive pulmonary aspergillosis may complicate chronic
obstructive pulmonary disease, particularly when treated with
oral corticosteroids (OCS), bacterial or viral pneumonia, sepsis,
liver failure, alcoholism or sinusitis.10–12
Our patient’s laboratory findings revealed no evidence of
neutropenia or immunosuppression, raising a suspicion of
whether his 2-year smoking history or 3-week history of OCS
use could have led to some abnormalities in the pulmonary
defence mechanism. This seemed an unlikely possibility as the
patient was symptomatic months before inhaled or OCS therapy
was prescribed.
The respiratory tract remains the primary focus of disease,
with poor disease control leading to mediastinal extension and
haematogenous dissemination that can involve any organ.13
The diagnosis of IA remains a challenge due to the absence
of specific clinical manifestations, non-pathognomonic radiological findings and poor sensitivity of sputum cultures. In
most cases, diagnosis is made by tissue isolation through invasive methods, as was the case in our patient. However, we
felt attempting a less invasive approach namely image-guided
fine-needle aspiration would have yielded the same results and
Rahim Y, et al. BMJ Case Rep 2018. doi:10.1136/bcr-2018-225614

should have been attempted first. Serological tests are adjuncts
to support or exclude the diagnosis in the appropriate clinical
context; however, they cannot be solely relied on for a definitive
diagnosis.
Published literature highlights the poor, usually fatal outcome
in patients with disease involving the mediastinum, despite initiation of antifungal therapy.14–16 This particularly holds truth in
cases with delayed diagnosis leading to treatment delay and fatal
outcomes. In this case, the patient continues to have a favourable
outcome, with ongoing follow-up.
Treatment is often prolonged, with the duration of treatment
determined empirically, depending on the extent of IA, the response
to therapy and the immune status of the patient. Voriconazole is
the first-line therapy for IA, with treatment duration depending
on disease burden and host immunocompetence. The Infectious
Diseases Society of America recommends 6 to 12 weeks of therapy
for pulmonary aspergillosis.16 In immunosuppressed patients,
therapy should be continued throughout the period of immunosuppression and until the resolution of lesions.16 Surgical treatment
is reserved for patients who do not tolerate antifungal therapy or
have residual localised but active lesions, despite adequate antifungal therapy.
This case highlights the importance of including the suspicion of IA in the differential diagnosis of a mediastinal mass
presenting with signs of SVC syndrome irrespective of immune
status, where TB and malignancy represent valid possibilities,
as disease outcome is directly linked with early diagnosis and
therapy.17 Early and timely treatment prevents future complications and death.

Learning points
►► Invasive aspergillosis (IA) is a rare but important

consideration in immunocompetent patients presenting with
signs of superior vena cava obstruction and a mediastinal
mass.
►► Suspicion of IA in a patient, who does not respond to
antibiotic or antituberculous therapy, is imperative in early
diagnosis, allowing timely initiation of aggressive antifungal
therapy and increasing the chances of a favourable outcome.
►► Imaging-guided percutaneous needle biopsy of mediastinal
masses should be attempted first before reverting to a more
invasive approach namely surgery.
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